These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12067675)

  • 1. New drug slows prostate-cancer progression.
    van der Boon J
    Lancet Oncol; 2002 Apr; 3(4):201. PubMed ID: 12067675
    [No Abstract]   [Full Text] [Related]  

  • 2. New principles in the treatment of hormonal refractory prostate cancer.
    Nisen P
    Scand J Urol Nephrol Suppl; 2003; (212):20-2. PubMed ID: 12841323
    [No Abstract]   [Full Text] [Related]  

  • 3. The endothelin-1 antagonist, atrasentan, improves time to progression and quality of life in hormone-refractory prostate cancer.
    Fisher M
    Clin Prostate Cancer; 2002 Sep; 1(2):79-80. PubMed ID: 15046697
    [No Abstract]   [Full Text] [Related]  

  • 4. Clinical trials of atrasentan in hormone-refractory prostate cancer.
    Lee D
    Clin Prostate Cancer; 2003 Sep; 2(2):84-6. PubMed ID: 15040868
    [No Abstract]   [Full Text] [Related]  

  • 5. Atrasentan: a rationally designed targeted therapy for cancer.
    Jimeno A; Carducci M
    Drugs Today (Barc); 2006 May; 42(5):299-312. PubMed ID: 16801993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan.
    Nelson JB; Nabulsi AA; Vogelzang NJ; Breul J; Zonnenberg BA; Daliani DD; Schulman CC; Carducci MA
    J Urol; 2003 Mar; 169(3):1143-9. PubMed ID: 12576870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.
    Thakkar SG; Choueiri TK; Garcia JA
    Curr Oncol Rep; 2006 Mar; 8(2):108-13. PubMed ID: 16507220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endothelin receptor antagonists in the treatment of prostate cancer.
    Nelson JB
    Prostate; 2001 Oct; 49(2):91-2. PubMed ID: 11582586
    [No Abstract]   [Full Text] [Related]  

  • 9. Endothelin inhibition: novel therapy for prostate cancer.
    Nelson JB
    J Urol; 2003 Dec; 170(6 Pt 2):S65-7; discussion S67-8. PubMed ID: 14610413
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrasentan prolongs time to progression in prostate cancer patients.
    Oncology (Williston Park); 2001 Jul; 15(7):833, 917. PubMed ID: 11499685
    [No Abstract]   [Full Text] [Related]  

  • 11. Endothelin receptor antagonists.
    Nelson JB
    World J Urol; 2005 Feb; 23(1):19-27. PubMed ID: 15654644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
    Carducci MA; Padley RJ; Breul J; Vogelzang NJ; Zonnenberg BA; Daliani DD; Schulman CC; Nabulsi AA; Humerickhouse RA; Weinberg MA; Schmitt JL; Nelson JB
    J Clin Oncol; 2003 Feb; 21(4):679-89. PubMed ID: 12586806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrasentan: targeting the endothelin axis in prostate cancer.
    Jimeno A; Carducci M
    Expert Opin Investig Drugs; 2004 Dec; 13(12):1631-40. PubMed ID: 15566319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atrasentan for metastatic hormone refractory prostate cancer.
    Murphy G
    Issues Emerg Health Technol; 2005 Dec; (77):1-4. PubMed ID: 16544441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Atrasentan demonstrates survival benefit in hormone-refractory prostate cancer.
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):245. PubMed ID: 12113043
    [No Abstract]   [Full Text] [Related]  

  • 16. Atrasentan Abbott.
    Norman P
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1240-8. PubMed ID: 12211423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.
    Nelson JB; Love W; Chin JL; Saad F; Schulman CC; Sleep DJ; Qian J; Steinberg J; Carducci M;
    Cancer; 2008 Nov; 113(9):2478-87. PubMed ID: 18785254
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The endothelin axis: emerging role in cancer.
    Nelson J; Bagnato A; Battistini B; Nisen P
    Nat Rev Cancer; 2003 Feb; 3(2):110-6. PubMed ID: 12563310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.
    Zonnenberg BA; Groenewegen G; Janus TJ; Leahy TW; Humerickhouse RA; Isaacson JD; Carr RA; Voest E
    Clin Cancer Res; 2003 Aug; 9(8):2965-72. PubMed ID: 12912943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of quality of life in men with metastatic hormone-refractory prostate cancer: how does atrasentan influence quality of life?
    Cella D; Petrylak DP; Fishman M; Teigland C; Young J; Mulani P
    Eur Urol; 2006 May; 49(5):781-9. PubMed ID: 16458417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.